The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | DNA methyltransferase inhibitors: daratumumab enhancement for MM
Priya Choudhry
• 14 Sep 2019
Priya Choudhry, PhD, from the University of California, San Francisco, CA, discusses how the use of DNA methyltransferase inhibitors upregulate CD38 expression and enhance daratumumab efficacy at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
